Automatic Website Traffic RSS

Arrowhead Pharmaceuticals - Finally, Another Buying Opportunity

Latest downturn in Arrowhead stock is unjustified as it is not based on any specific news item. Upcoming earnings and cash concerns are what investors should be focused on short-term. Look for a ... read more

Is Arrowhead Pharmaceuticals a Buy? | The Motley Fool

In October 2018, Arrowhead Pharmaceuticals inked a collaboration deal with Johnson & Johnson subsidiary Janssen to develop what they hope can become a functional cure for chronic hepatitis B (CHB). read more

Buy Rating Affirmed for Arrowhead Pharmaceuticals Following Promising Plozasiran Trial Results - Markets Insider

Analyst Patrick Trucchio of H.C. Wainwright reiterated a Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report), retaining the price target of $90.00. Patrick Trucchio has given his ... read more

Is Arrowhead Pharmaceuticals a Buy Now? - Nasdaq

If so, you'll want to check out Arrowhead Pharmaceuticals (NASDAQ: ARWR). SVB Securities, ... Is Arrowhead Pharmaceuticals a Buy Now? April 16, 2023 — 05:21 am EDT. read more

Does Arrowhead Pharmaceuticals (ARWR) Have a Long Runway for Growth?

On May 9, 2023, Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) stock closed at $40.47 per share. One-month return of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) was 41.70%, and its shares gained ... read more

Buy Rating Affirmed for Arrowhead Pharmaceuticals Amid Promising Plozasiran Developments - Markets Insider

Patrick Trucchio, an analyst from H.C. Wainwright, reiterated the Buy rating on Arrowhead Pharmaceuticals (ARWR – Research Report). The associated price target was lowered to $60.00. Patrick ... read more

Chardan Capital Reiterates Arrowhead Pharmaceuticals (ARWR) Buy Recommendation - Nasdaq

Fintel reports that on August 8, 2023, Chardan Capital reiterated coverage of Arrowhead Pharmaceuticals (NASDAQ:ARWR) with a Buy recommendation. Analyst Price Forecast Suggests 130.62% Upside ... read more

Is Arrowhead Pharmaceuticals a Buy Now? | The Motley Fool

Arrowhead Pharmaceuticals is a precommercial-stage drugmaker with 12 candidates now in clinical trials. This highly productive biopharmaceutical company expects to bring eight more drug candidates ... read more